The Supreme Court's decision to overturn Roe v. Wade opened the door to allow states to ban or severely restrict abortion. But as biotech CEO Aoife Brennan and her colleagues are coming to realize, it will also affect how — and perhaps where — clinical trials are conducted. This week on the "First Opinion Podcast," Brennan, of Synlogic, talks about how the Supreme Court's ruling is forcing people involved in clinical research to rethink something as simple as pregnancy tests, which had once been taken for granted, and plan for the possibility that research sponsors and study sites will be required to share pregnancy and outcome data with state officials.
